-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Alopexx, Inc. Prices IPO at $5.00 Per Share (ALPX)
Alopexx, Inc. Prices IPO at $5.00 Per Share (ALPX)
$Alopexx (ALPX.US)$ expects to raise $15 million in an initial public offering on the week of September 26th, IPO Scoop reports. The company will issue 3,000,000 shares at $5.00 per share.
The company has a market-cap of $39.2 million.
ThinkEquity acted as the underwriter for the IPO.
Alopexx, Inc. provided the following description of their company for its IPO: "We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management's assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine's broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis and sexually transmitted diseases. Similarly, our fully human monoclonal antibody, F598, which also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials. We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU). Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation. Note: Net loss is for the year ended Dec. 31, 2021. **Note: As of June 30, 2022, we had an accumulated deficit of $5.99 million. Alopexx says that it has three officers and no employees before the IPO, according to the prospectus. (Note: Alopexx, Inc. increased the size of its IPO to 3.0 million shares, up from 2.5 million shares, and cut the price to $5.00, the bottom of its previous $5.00-to-$7.00 range, to raise $15 million (same estimate as before), according to an S-1/A filing dated Sept. 6, 2022. Alopexx disclosed its IPO terms – 2.5 million shares at $5.00 to $7.00 to raise $15 million – in an S-1/A filing dated Aug. 24, 2022. Alopexx filed an S-1/A dated April 20, 2022, disclosing that its proposed stock symbol is "ALPX". On March 4, 2022, Alopexx filed its S-1. The company filed confidential IPO documents with the SEC on Jan. 7, 2022.) ".
Alopexx, Inc. was founded in 2006 and has 0 employees. The company is located at 186 Alewife Brook Pkwy #1068 Cambridge, Massachusetts 02138 and can be reached via phone at (617) 780-1598
$Alopexx (ALPX.US)$ expects to raise $15 million in an initial public offering on the week of September 26th, IPO Scoop reports. The company will issue 3,000,000 shares at $5.00 per share.
$Alopexx (ALPX.US)$IPO Scoop報道,預計將在9月26日當週的首次公開募股中籌集1500萬美元。該公司將以每股5.00美元的價格發行300萬股股票。
The company has a market-cap of $39.2 million.
該公司的市值爲3920萬美元。
ThinkEquity acted as the underwriter for the IPO.
ThinkeQuity擔任了首次公開募股的承銷商。
Alopexx, Inc. provided the following description of their company for its IPO: "We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management's assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine's broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis and sexually transmitted diseases. Similarly, our fully human monoclonal antibody, F598, which also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials. We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU). Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation. Note: Net loss is for the year ended Dec. 31, 2021. **Note: As of June 30, 2022, we had an accumulated deficit of $5.99 million. Alopexx says that it has three officers and no employees before the IPO, according to the prospectus. (Note: Alopexx, Inc. increased the size of its IPO to 3.0 million shares, up from 2.5 million shares, and cut the price to $5.00, the bottom of its previous $5.00-to-$7.00 range, to raise $15 million (same estimate as before), according to an S-1/A filing dated Sept. 6, 2022. Alopexx disclosed its IPO terms – 2.5 million shares at $5.00 to $7.00 to raise $15 million – in an S-1/A filing dated Aug. 24, 2022. Alopexx filed an S-1/A dated April 20, 2022, disclosing that its proposed stock symbol is "ALPX". On March 4, 2022, Alopexx filed its S-1. The company filed confidential IPO documents with the SEC on Jan. 7, 2022.) ".
Alopexx, Inc. 對其公司的首次公開募股提供了以下描述:“我們是一家臨床階段的生物技術公司,正在開發用於預防、治療和緩解表達抗原靶聚N-乙酰氨基葡萄糖(PNAG)的細菌、真菌和寄生蟲感染的新型免疫療法。在越來越多的病原體上發現了該靶標。儘管我們療法的安全性和有效性的最終決定將由美國食品藥品管理局和其他衛生當局決定,但我們的管理層評估認爲,我們的療法的廣譜潛力將使它們能夠用於預防、治療和緩解各種感染。在一項首次人體試驗中,我們的候選疫苗 AV0328 已被證明具有良好的耐受性,沒有觀察到嚴重的不良事件。有人指出,它可以誘發針對所有測試的表達 pnAG 的病原體的保護性抗體。我們認爲,我們的疫苗的廣譜潛力將使其能夠用於長期預防各種感染,包括肺炎球菌肺炎、耐甲氧西林金黃色葡萄球菌(MRSA)、腦膜炎和性傳播疾病。同樣,我們的全人源單克隆抗體F598(也靶向PNAG)已被證明具有良好的耐受性,在1期和試點2期試驗中沒有發現嚴重的不良事件。我們相信它可以提供持續 2-3 個月的即時保護。我們力求將F598確立爲預防和改善革蘭陰性和革蘭氏陽性細菌感染以及重症監護病房(ICU)患者中表達 PNAG 的生物的真菌感染的護理標準。這些療法的利用在傳染病之外還有潛在的適用性,包括治療神經系統疾病和炎症導致的認知能力下降。注意:淨虧損是截至2021年12月31日的財年。**注意:截至2022年6月30日,我們的累計赤字爲599萬美元。根據招股說明書,Alopexx表示,在首次公開募股之前,它有三名高管,沒有員工。(注意:根據2022年9月6日的S-1/A文件,Alopexx, Inc.將其首次公開募股規模從250萬股增加到300萬股,並將價格下調至5.00美元,這是之前的5.00至7.00美元區間的底部,籌集了1500萬美元(與之前的估計相同)。Alopexx在2022年8月24日的一份S-1/A文件中披露了其首次公開募股條款——250萬股,價格爲5.00美元至7美元,籌集1500萬美元。Alopexx 於 2022 年 4 月 20 日提交了 S-1/A,披露其擬議的股票代碼爲 “APX”。2022 年 3 月 4 日,Alopexx 提交了 S-1。該公司於 2022 年 1 月 7 日向美國證券交易委員會提交了機密的 IPO 文件。)”。
Alopexx, Inc. was founded in 2006 and has 0 employees. The company is located at 186 Alewife Brook Pkwy #1068 Cambridge, Massachusetts 02138 and can be reached via phone at (617) 780-1598
Alopexx, Inc. 成立於 2006 年,擁有 0 名員工。該公司位於 186 Alewife Brook Pkwy #1068 馬薩諸塞州劍橋 02138,可以通過電話 (617) 780-1598 與該公司聯繫
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧